Compare Godaddy Inc (GDDY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs BIO-TECHNE Corp — how do they compare? Godaddy Inc trades at $90.75 (market cap $11.59B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Godaddy Inc and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| GDDY | TECH | |
|---|---|---|
Market Cap | $11.59B | $11.24B |
Sector | Technology | Health |
52-Week High | $148.88 | $72.29 |
52-Week Low | $75.07 | $43.31 |
Enterprise Value | $14.27B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $91.07, up 0.8% today, with a neutral technical signal and strong fundamentals including a P/E of 13.53 and net income margin of 17.83%. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $1.83 surpassing the $1.69 expectation. However, the stock faces headwinds from multiple law firm investigations into potential securities violations, as reported by PRNewsWire and GlobeNewsWire in early August 2026.
The outlook is mixed: analyst consensus is bullish with a $112.13 price target (56.76% buy ratings), but legal risks and a high debt load pose concerns. Revenue growth is steady, projected at $5.1B for 2026, yet investor sentiment is cautious due to ongoing litigation. Upside depends on clearing legal hurdles and maintaining earnings momentum.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
